Departmental Seminars

Every weekday, until 27th Nov 2017

2017 Seminars - No RSVP required

The changing landscape of cervical cancer in the era of HPV vaccination
Dr Dorothy Machalek, Postdoctoral Research Fellow
Department of Microbiology & Infectious Diseases, The Royal Women’s Hospital
Monday 22 May, 12.30pm, Seminar Rooms 7D/E, Level 7, The Royal Women’s Hospital

HPV Brochure Dorothy Machalek is an early career epidemiologist, specialising in human papillomavirus (HPV) prevention research. She is currently leading a Commonwealth Department of Health funded HPV vaccine evaluation program at the Royal Women’s Hospital. The program aims to track the prevalence of HPV infection, both vaccine and non-vaccine types over time, to make sure the National HPV Vaccination Program is doing what it is supposed to do in preventing infections. In her talk, Dorothy will review the epidemiology of HPV, including its role in cervical and other cancers, as well as the impact of HPV vaccination in Australia.


Future directions in female oncofertility
Dr Quynh-Nhu Nguyen, PhD Student
Department of Obstetrics & Gynaecology, The University of Melbourne
Monday 29 May, 12.30pm, Seminar Rooms 7D/E, Level 7, The Royal Women’s Hospital


In females, a common side-effect of DNA-damaging cancer treatments is destruction of primordial follicles, resulting in premature ovarian failure and infertility. However, the precise mechanisms involved in chemotherapy-mediated follicle depletion are unclear. We used mouse knock-out models to examine the role of the potent pro-apoptotic protein, PUMA, and its transcriptional activator TAp63, in ovarian reserve depletion caused by cyclophosphamide or cisplatin, and the effects of these treatments on long-term fertility. Results have significant implications for our understanding of chemotherapy-induced follicle loss, and for the future development of potential ovoprotective therapies.


Professor Eva Dimitriadis, NHMRC Senior Research Fellow
Head Embryo Implantation Laboratory, Hudson Institute of Medical Research
Monday 19 June, 12.30pm, Seminar Rooms 7D/E, Level 7, The Royal Women’s Hospital


Going Viral: Introduction to Media and Social Media
Krista Eleftheriou, Media Manager and Michelle Carnovale, Senior Media Advisor
Communications Department, The Royal Women's Hospital
Monday 26 June, 12.30pm, Seminar Rooms 7A/B, Level 7, The Royal Women’s Hospital

7.30 Report film crew filming at RWH

This presentation explores what makes news, how the Women's can raise its profile, the opportunities to reach and engage a broader audience through social media and tips and pitfalls when engaging in media and social media.


How can we prevent advanced anal cancer in women?
Dr Alyssa M. Cornall, Research Officer, Centre for Women's Infectious Disease
Royal Women's Hospital; MCRI; Dept. of Obstetrics & Gynaecology, University of Melbourne
Monday 10 July, 12.30pm, Seminar Rooms 7D/E, Level 7, The Royal Women’s Hospital

Diagram of anal cancer

Anal cancer is a rare but increasingly prevalent cancer. Although gay and bisexual men are at highest risk, more cases are diagnosed in women than in men. Treatment of early cancers can be highly successful with high survival and minimal need for physically destructive surgery, yet around 50% of anal cancers have spread beyond the local area at the time of diagnosis. Rarity, stigma, lack of symptoms and lack of consensus on screening make prevention or early detection of anal cancer difficult. However there are known risk factors and other health services in place that can contribute to primary prevention, screening for pre-cancer and early detection of anal cancer in women.


What microbial factors contribute to the development of bacterial vaginosis?
Gerald Murray, Senior Research Officer
The Royal Women’s Hospital
Monday 18 September, 12.30pm, Seminar Rooms 7D/E, Level 7, The Royal Women’s Hospital


Bacterial vaginosis (BV) is a common disorder characterised by a disruption of the normal vaginal bacterial community. BV is associated with increased risk of acquisition and transmission of sexually transmitted diseases, including HIV. BV is also linked to adverse obstetric outcomes such as low birth weight and premature delivery. Treatment has limited success, with recurrence levels of around 50%. This seminar will outline the current knowledge of BV, focusing on microbial factors that contribute to the disorder.